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ABSTRACT  
CAP1/Prss8 is a membrane-bound serine protease involved in the regulation of several 
different effectors, such as the epithelial sodium channel ENaC, the protease-activated 
receptor PAR2, the tight junction proteins and the profilaggrin polypeptide. Recently, the 
V170D and the G54-P57 deletion mutations within the CAP1/Prss8 gene, identified in 
‘frizzy’ mice (fr) and ‘hairless’ rats (frCR) respectively, have been proposed as causative of 
their skin phenotypes. In the present study, we analyzed those mutations revealing a change in 
the protein structure, a modification of the glycosylation state, and an overall reduction in the 
activation of ENaC of the two mutant proteins. In vivo analyses demonstrated that both fr and 
frCR mutant animals present analogous reduction of embryonic viability, similar histological 
aberrations at the level of the skin, and a significant decrease in the activity of ENaC in the 
distal colon in comparison with their control littermates. ‘hairless’ rats additionally showed 
dehydration defects in skin and intestine and significant reduction in the body weight. In 
conclusion, we provided molecular and functional evidences that CAP1/Prss8 mutations are 
accountable for the defects in fr and frCR animals, and we furthermore demonstrated a 
decreased function of the CAP1/Prss8 mutant proteins. Therefore, fr and frCR animals 
emerged as suitable models to investigate the consequences of CAP1/Prss8 action on its target 
proteins in the whole organism.  
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INTRODUCTION 
Proteolytic enzymes and their inhibitors count up for more than 2% of the known proteome 
and a crucial role of these proteins in tissue homeostasis, diseases and development is well 
demonstrated 1,2,3,4.  
CAP1/Prss8 (also known as prostasin) is a glycosyl-phosphatidylinositol membrane-anchored 
serine protease expressed in the epithelium of various organs, such as prostate, kidney, lung, 
colon and skin 5,6,7. CAP1/Prss8 was the first of several membrane-tethered serine proteases 
found to activate the amiloride-sensitive epithelial sodium channel ENaC in a kidney 
epithelial cell line, and for this reason it was named channel-activating protease 1 (CAP1) 8,9. 
These findings predicted that CAP1/Prss8 has an important role in regulating the epithelial 
sodium transport in vivo 10, and ENaC currents became a suitable parameter to monitor 
CAP1/Prss8 activity.  
CAP1/Prss8 has also been demonstrated to play essential functions in the physiopathology of 
lung and skin. CAP1/Prss8 inactivation addressed to the alveolar epithelium decreased ENaC-
mediated alveolar sodium transport, and increased alveolar lining fluid volume in an 
experimental model of acute volume-overload 6. The lack of CAP1/Prss8 in the skin caused 
early postnatal mortality because of severe skin dehydration defects, altered the processing of 
profilaggrin and generated defective tight junctions 7. On the other hand, CAP1/Prss8 
overexpression in the skin severely impaired the epidermal barrier function and provoked 
ichthyosis and inflammation. Those pathological features were completely negated when 
superposed on a protease-activated receptor 2 (PAR2) knock-out background, placing PAR2 
as a downstream effector of CAP1/Prss8 1. PAR2 is a G-protein-coupled receptor also 
involved in neural tube closure and it can be activated by local proteases as CAP1/Prss8 for 
regulating epithelial integrity 11. Moreover, CAP1/Prss8 was found down-regulated in 
hormone refractory prostate cancers, gastric and breast cancer 12,13,14, and up-regulated in 
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epithelial ovarian cancer 15, suggesting an additional role of CAP1/Prss8 in tumor invasion. 
Thus, CAP1/Prss8 emerged as involved in various different processes that range from organ 
integrity to disease. 
Very recently, Spacek and colleagues located the genetic defects in the spontaneous ‘frizzy’ 
mouse (fr) and ‘hairless’ rat (frCR) models on the CAP1/Prss8 gene 16. Mice carrying the fr 
mutation in homozygosity display a nearly normal, wavy coat, and distinctly curly vibrissae 
that are apparent after birth and persist throughout life 17. The Charles River ‘hairless’ rat frCR 
is one of the autosomal recessive hypotrichotic models actively studied in pharmacologic and 
dermatologic research, and it is characterized by almost complete baldness 18. Spacek and 
coworkers demonstrated that the fr mutation consists of a T to A transversion in the 
CAP1/Prss8 gene that results in a valine to aspartate substitution at residue 170. The 
assignment of fr mutation on the CAP1/Prss8 gene was supported by complementation test 
that indicated the failure of the knock-out allele (Δ) of CAP1/Prss8 19 to complement the fr 
defect in compound heterozygotes (fr/Δ). In addition, sequence analysis of CAP1/Prss8 
coding regions in the ‘hairless’ frCR rat identified a 12-bp deletion in the third exon leading to 
G54-P57 ablation in the CAP1/Prss8 protein, indicating that mouse fr and the rat frCR 
mutations may indeed be orthologues 16, as already suggested by previous studies 20. 
Therefore, the V170D missense and G54-P57 deletion mutations in the CAP1/Prss8 gene 
have been proposed as the molecular bases for the fr mouse and frCR rat variants, respectively.  
Aiming to investigate whether these genetic data could be supported by molecular and 
functional evidences, we analyzed the consequences of those mutations, and performed in 
silico, in vitro and in vivo experiments. V170D and G54-P57 deletion mutations changed 
CAP1/Prss8 protein structure and reduced ENaC activation in the Xenopus laevis oocyte cell 
system. Inheritance, histological and functional studies of fr/fr, fr/Δ mice and frCR/frCR rats in 
comparison with littermate control groups, unveiled very similar features among these 
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variants, defined by reduced embryonic viability, skin abnormalities, and decreased ENaC 
activity in the distal colon. Therefore, we could demonstrate, at the molecular and functional 
level, that the fr and frCR phenotypes are caused by V170D and G54-P57 deletion mutations in 
the CAP1/Prss8 gene. Finally, fr and frCR animals emerged as suitable models for CAP1/Prss8 
reduced function in the whole organism. 
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MATHERIALS AND METHODS 
Homology modeling, in silico alanine scanning and amino acid alignment 
Mouse CAP1/Prss8 45-290 sequence fragment obtained from the CAP1/Prss8 entry Q9ESD1 
at the UniProt knowledgebase 21 was a target sequence for homology modeling of murine 
CAP1/Prss8 structure. As a template the crystal structure of human homologous protein 
available in the protein structures database under the 3DFJ code was used 22. The alignment 
between the two sequences was built using the Modeller 9v5 program 23. A very high, 80% 
sequence identity between the target and the template sequence in the calculated alignment 
implies a good reliability of the final model. The standard modeling procedure using spatial 
restraints derived from the alignment was performed with Modeller 9v5. The 100 models 
were constructed and their ANOLEA scores 24 were calculated. The model with the best 
overall ANOLEA score was chosen for further studies. The quality of the model was checked 
with the PROCHECK software. Noteworthy, no residues were appearing in the disallowed 
regions of Ramachandran plot and 91.1% of residues appeared in the most favored regions of 
the plot indicating the good quality of the structure. The FoldX program 25 was employed to 
perform a computational alanine scan by mutating selected residues to an alanine and 
estimating the change in the protein stability. Amino acid alignment was performed by using 
the clustalw2 program (http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
Construct preparation, Xenopus oocyte injections, electrophysiological measurements 
and HEK-293 cells transfections 
The T to A transversion that results in a valine to aspartate substitution at residue 170, and the 
GGTCAGTGGCCC deletion that results in G54-P57 ablation in the transcribed protein, were 
each inserted into the mouse CAP1/Prss8 coding sequence (Genbank g.i. 19111159) and 
introduced in the pSDeasy expression vector, a modified pSD5 vector 26, for in vitro 
transcription. SP6 RNA polymerase (Promega) was used for cRNA synthesis.  
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Expression studies performed in Xenopus laevis oocytes (Noerdhoek, South Africa) in stage 
V/VI, were described previously 27. A total of 0.25 ng of each cRNA encoding the three rat 
ENaC subunits in the presence or absence of 2 ng of wild-type or mutant CAP1/Prss8 cRNA 
in a total volume of 50 nl was injected into oocytes. Oocytes were incubated in modified 
Barth saline solution. Twenty-four hours after cRNA injection, electrophysiologic 
measurements were performed using the two-electrode voltage clamp technique. The 
amiloride-sensitive current was measured in the presence of 120 mM Na+ in frog Ringer with 
and without 5 µM amiloride and without 20mg/ml of trypsin at a holding potential of -80mV.  
Wild-type and mutant mouse CAP1/Prss8 coding sequences were inserted in the pRK5 
expression vector for HEK-293 cells transfection. HEK-293 were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum and gentamycin 
(100 µg/ml) and transfected at 50–60% confluence in 100-mm dishes using the calcium-
phosphate method. After transfection, cells were grown for 48 h in DMEM supplemented 
with 10% fetal calf serum before harvesting. The total amount of transfected DNA was 12 
µg/100-mm dish.  
Western blot and pulse-chase experiments 
Xenopus oocytes were homogenized in Triton X-100 1%, Tris-HCl 20 mM, pH 7.6 and NaCl 
100 mM. Lysates were centrifuged (13,000 g for 10 min at 4 °C). HEK-293 cells were lysed 
using 1 ml of lysis buffer per dish of 1% Triton Buffer (20mM Tris-HCl pH7.4, 150mM 
NaCl, 1% Triton X-100, 100mM leupeptin, pepstasin and aprotinin, 10mM PMSF). HEK-293 
cells lysates were incubated 1 h at 4 °C on a rotating wheel. The solubilized material was 
centrifuged at 10,000 x g for 30 min at 4 °C and the supernatants were collected. Animal 
tissues were lysed in 1 ml of RIPA buffer (50mM Tris-HCl pH7.2, 150mM NaCl, 1% NP-40, 
0.1% SDS, 0.5% Na-deoxycholate, 100mM leupeptin, pepstasin and aprotinin, 10mM 
PMSF). Lysates were centrifuged (13,000 g for 15 min at 4 °C) and the supernatants were 
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collected. For SDS-PAGE, samples were loaded and separated on a 10% polyacrylamide gel. 
Western blot analysis was performed using rabbit anti-mouse antibodies to CAP1/Prss8 28. 
Signals were revealed using anti-rabbit immunoglobulin G from goat (1:10,000) as secondary 
antibody and the SuperSignal West Dura detection system (Pierce).  
To study CAP1/Prss8 protein expression, cRNA-injected oocytes were incubated in modified 
Barth’s solution (MBS) containing 0.7-1 mCi/ml [35S]methionine for 6 h and subjected to 4- 
and 16-h chase periods in MBS containing 10 mM unlabeled methionine. After the pulse-
chase periods, protein extracts were prepared and subjected to non-denaturing immune-
precipitations 29. After overnight incubation at 4°C with CAP1/Prss8 antibody, the immune-
complexes were recovered on protein A Sepharose beads (GE Healthcare) and washed several 
times with MBS containing unlabeled methionine. Immunoprecipitates were resolved by 
SDS-PAGE (10% polyacrylamide) gels. 	
Isolation of rat alveolar epithelial cells  
The procedure of rat alveolar epithelial cell (AEC) isolation accorded with legislation 
currently in force in France and Switzerland, and animal welfare guidelines (Ministère 
Français de la Pêche et de l’Agriculture, agreement # 5669). Alveolar epithelial cells were 
isolated from adult wild type, heterozygous and homozygous mutant rats by elastase digestion 
of lung tissue followed by sequential filtration and differential adherence on bacteriological 
dishes as previously described 28. Cell purity was >80%, and cell viability > 95%.  
Preparation of alveolar epithelial cell protein extracts and Western blotting procedure  
Freshly isolated rat AEC were resuspended in 30 µl of ice-cold lysis buffer containing 150 
mM NaCl, 50 mM Tris-HCl (pH 7.6), 1% Triton X-100, 0.1% SDS, and protease inhibitors, 
and kept on ice for 1h. Cell lysates were then centrifuged (12,000 rpm, 15 min) at 4°C, and 
samples of the supernatants were immediately frozen before use. For Western blotting, 
samples of protein extracts (40 µg protein) in one volume of sample buffer (containing 13.8% 
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sucrose, 9.6% SDS, 4.2% beta-mercaptoethanol, and 0.0126% bromophenol blue in H2O) 
were resolved through 10% acrylamide gels, electroblotted, electrically transferred to PVDF 
membranes, and subsequently probed for CAP1 protein detection. The goat anti-rabbit IgG 
secondary antibody (Santa Cruz Biotechnology) was used at dilution 1:3,000, and the signal 
was developed with the Western Bloting Luminol Reagent (Santa Cruz Biotechnology). 
Animal genotyping and stool assay 
The genotype of fr mouse and frCR rat animal models (kindly provided by Dr. Thomas R. 
King; Biomolecular Sciences, Central Connecticut State University, 1615 Stanley Street, New 
Britain, CT 06053, USA) was assessed as formerly described 16. We previously reported the 
generation and genotyping of the engineered null allele (Δ) of CAP1/Prss8 19. Experimental 
procedures and animal maintenance followed federal guidelines and were approved by local 
authorities. All animals were housed in a temperature and humidity controlled room with an 
automatic 12 h light/dark cycle, and had free access to food and tap water.  
Faecal hydration was assessed as following: freshly evacuated stools were collected in the 
morning, and weighted prior to and after at least 2 hours of dehydration performed by using 
the SpeedVac. Values are expressed as mean of the difference in weight ± s.e.m. 
RNA extraction and quantitative RT-PCR.  
Cells and organs were homogenized using Tissue Lyser (Qiagen) and RNA was extracted 
with the Qiagen RNeasy Mini kit following the manufacturer’s instructions. 1 µg of RNA was 
reverse-transcribed using M-MLV Reverse Transcriptase RNase H Minus Point Mutant 
(Promega). Real-time PCR was performed by TaqMan PCR using Applied Biosystems 7500. 
Each measurement was taken in duplicate. Quantification of fluorescence was normalized to 
beta-actin. Primer and probe sequences were published previously 1. 
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Immunofluorescence and histology  
Cells and organs were embedded into paraffin. Slides were incubated in xylene for at least 
four hours and rinsed with decreasing concentrations of ethanol. Antigen retrieval was 
performed for 10 min in TEG buffer. Slides were washed in 50 mM NH4Cl in PBS for 30 
min and blocked by 1% BSA, 0.2% gelatine, 0.05% Saponin in PBS at room temperature for 
10 min, three times. Primary antibody was diluted in 0.1% BSA, 0.3% Triton X-100 in PBS, 
overnight at 4 °C. Affinity-purified CAP1/Prss8 rabbit anti-mouse antiserum 28 was diluted 
1:200. Slides were rinsed three times for 10 min in PBS containing 0.1% BSA, 0.2% gelatine 
and 0.05% saponin at room temperature and the secondary antibody (Alexa Fluor 488, diluted 
1:5,000) was diluted in 0.1% BSA, 0.3% Triton X-100 in PBS. Staining was visualized using 
an LSM confocal microscope (LSM 510 Meta, Carl Zeiss MicroImaging Inc.).  
Hematoxylin and eosin colorations were performed as following: the paraffine was removed 
and the slides re-hydrated 2x in xylol for 5’, 2x in 100% ethanol for 1 min, in 95% ethanol for 
1 min and finally with tap water. The coloration was performed as follows: Glychemalun 
solution (Hematein 0.013 M, Gurr #34036; potassium alum 0.3133 M, Merk #1047; 30% 
glycerol; 1% acetic acid Merk #1.00063) for 4 min, tap water, 1% acid alcohol for 3 sec, tap 
water, water for 15 sec plus a few drops of NH3, tap water, 0.2% erythrosine solution 
(Erythrosin 0.0023 M, Merk #15936; Formol 0.1%, Merk #4003) for 30 sec and finally tap 
water. Slides were then de-hydrated by following steps from 70% ethanol to xylol and 
mounted (Eukitt). Pictures were taken using an Axion HRC (Carl Zeiss MicroImaging Inc.). 
Measurement of trans epithelial water loss (TEWL) and rectal trans epithelial potential 
difference (PD) 
The rate of TEWL from the ventral skin of pre-shaved, anaesthetized animals was measured 
using a Tewameter TM210 (Courage and Khazaka). The mean ± s.e.m. is shown. 
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Rectal PD and amiloride-sensitive rectal PD were measured in the morning (10 a.m –12 p.m.) 
and in the afternoon (4 p.m. – 6p.m.) of two different days of the same week. Animals were 
anaesthetized with an intra-peritoneal injection of Ketalar (Park-Davis, Baar, Switzerland; 75 
mg/g bodyweight) and Rompun (Bayer, Leverkusen, Germany; 2.3 mg/g bodyweight) and 
placed on a heated table. A winged needle filled with isotonic saline was placed in the 
subcutaneous tissue of the back. A double-barreled pipette was prepared from borosilicate 
glass capillaries (1.0 mm OD/0.5 mm ID; Hilgerberg, Malsfeld, Germany) and pulled to an 
approximate 0.2 mm tip diameter. The first barrel was filled with isotonic saline buffered with 
10 mM Na+-HEPES (pH 7.2) and the second barrel was filled with the same solution 
containing 25 mM amiloride. The tip of the double-barreled pipette was placed in the rectum 
approximately 3-5 mm from the skin margin. The electrical PD was measured between the 
first barrel and the subcutaneous needle, both connected to Ag/AgCl electrodes by means of 
plastic tubes filled with 3 mM KCl in 2% agar. The rectal PD was monitored continuously by 
a VCC600 electrometer (Physiologic Instruments, San Diego, CA, USA) connected to a chart 
recorder. After stabilization of the rectal PD (approximately 1 min), 0.05 ml saline solution 
was injected through the first barrel as a control manoeuvre and the PD was recorded for 
another 30 sec period. A similar volume of saline solution containing 25 mM amiloride was 
injected through the second barrel of the pipette and the PD was recorded for another 1 min. 
The amiloride-sensitive PD was calculated as the difference between the PD recorded before 
and after the addition of amiloride.  
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RESULTS 
 
Reduced ENaC activation of V170D and G54-P57 CAP1/Prss8 deletion mutant proteins. 
Taking the advantage of the in silico protein modeling technique, we built the homology 
model of the mouse CAP1/Prss8 (Fig. 1A), using as template the crystal structure-based 
homology model of human CAP1/Prss8 30. V170 belongs to one of the beta strands in the 
inside of the protein, and is located in a hydrophobic environment. V170 makes hydrophobic 
contacts with the methyl groups of V256 and L191. The alanine scanning for V170 resulted in 
2.4 Kcal loss of energy upon mutation to Ala. G54-P57 residues (Gly-Gln-Trp-Pro) in 
CAP1/Prss8 are found on the external surface of the molecule and therefore solvent-exposed. 
This fragment, which is deleted in the frCR/frCR mutant rats, contains the structurally important 
Trp56 leading to 4.5 Kcal loss in stability when mutated to Ala. Multiple sequence alignments 
illustrated that the mutated residues are conserved among different species (Fig. 1B). 
To investigate the consequences of the V170D and G54-P57 deletion mutations on 
CAP1/Prss8 expression and function, we introduced V170D and G54-P57 deletion mutations 
in the mouse CAP1/Prss8, inserted the cDNA sequences in the pSDeasy expression vector for 
in vitro transcription 26, and co-injected CAP1/Prss8 and ENaC cRNA in the Xenopus 
oocytes. CAP1/Prss8 cRNA stability was estimated by real-time PCR, and no remarkable 
difference in the level of each V170D and G54-P57 deletion mutant versus wild-type 
CAP1/Prss8 was observed (data not shown). CAP1/Prss8 immuno-staining was detected at 
the plasma membrane in oocytes that were injected with wild-type CAP1/Prss8, and equal 
results were obtained with V170D and G54-P57 deletion CAP1/Prss8 mutants (Fig. 2A). 
Western blot analysis against CAP1/Prss8 evidenced the presence of two bands, of 37 and 40 
KDa, that might correspond to two different glycosylation states of the protein, and showed 
that the two mutant proteins can be translated as well as the wild-type (Fig. 2B). 
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Glycosylation of CAP1/Prss8 was assessed by treatment of oocyte extracts with the de-
glycosylating enzyme PNGase F, that revealed the presence of a non-glycosylated (n) native 
form upon de-glycosylation treatment. Thus, the two bands of 37 and 40 KDa, most likely 
correspond to the core-glycosylated form (c), which is typical of newly synthetized proteins, 
and the fully-glycosylated form (f) characteristic of mature proteins, respectively (Fig. 2C). 
Analogous results were obtained in transfected HEK-293 cells (Fig. 2D). 
To get further insight not only into the production but also into the degradation of wild-type 
and mutant proteins, we performed pulse-chase experiments by pulsing radioactively the 
oocytes during 6 hours (P) and chasing them during 4 (C1) and 16 (C2) hours in unlabeled 
media. Wild-type CAP1/Prss8 protein production was evident after 6 hours of pulse, and 
protein degradation was observed already following the first chase period. Similar results 
were obtained for the two mutant proteins. However, CAP1/Prss8 V170D and G54-P57 
deletion mutants showed different glycosylation states in comparison with the wild-type 
CAP1/Prss8, evidencing an increased fully-glycosylated state of the G54-P57 deletion mutant 
versus an increased core-glycosylated state of the V170D mutant (Fig. 2E).  
Co-expression of wild-type CAP1/Prss8 with ENaC leads to a significant increase in the 
amiloride-sensitive sodium current in the Xenopus oocyte cell system 31, hence ENaC current 
is considered an appropriate parameter to monitor CAP1/Prss8 activity. Trypsin can activate 
near-silent ENaC channels by dramatically increasing its open probability, indicating maximal 
ENaC activity of the cells 32. Co-injection of wild-type CAP1/Prss8 and ENaC revealed a 3.7-
fold significant increase in the amiloride-sensitive sodium current relative to trypsin, 
compared to oocytes that were injected with ENaC alone. In contrast, when either 
CAP1/Prss8 V170D or G54-P57 deletion mutant was co-expressed with ENaC, the ability of 
CAP1/Prss8 to increase ENaC-mediated currents was significantly reduced, leading to a 2.8 
and 2.1-fold increase relative to trypsin, respectively (Fig. 2F).  
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Reduced viability and similar hair phenotype in fr mouse and frCR rat models. 
To study the consequences of CAP1/Prss8 V170D and G54-P57 deletion mutations and to 
investigate whether they might be responsible of the phenotypes observed in the fr mouse and 
frCR rat models, we performed inheritance, histopathological, molecular and functional 
analyses of fr/fr, fr/Δ and frCR/frCR versus control littermates. 
Each fr/fr and fr/Δ mouse variants presented reduced prenatal viability, deriving from crosses 
fr/+ x fr/Δ, yielding only about 16% fr/fr and 13% fr/Δ mutant offspring respectively, rather 
than the expected 25%. frCR/+ x frCR/+ rat crosses generated 10% frCR/frCR mutants instead of 
the expected 25%. 83% of the frCR/frCR rats resulted in males (Table I).  
fr/fr, fr/Δ and frCR/frCR animals were distinguishable from their siblings as soon as the hair 
started to grow. In comparison to wild-type controls, fr/fr mice manifested curly whiskers and 
a wavy coat. The phenotype of fr/Δ animals was more severe, showing curly whiskers 
accompanied by less and shorter hair. frCR/frCR rats were almost completely bald. These data 
are in accordance with previous observations 16,20.   
No histopathological aberrations were observed in lung, kidney and distal colon. In contrast, 
fr/fr, fr/Δ mice and frCR/frCR rats presented hair bulbs deeply positioned in the lower dermis. In 
addition, frCR/frCR skin exhibited hyperplasic epidermis and hyperkeratosis, as well as swelled 
and more abundant sebaceous glands. Beside these structural and morphological defects, no 
signs of inflammation, such as cellular infiltrations, were detectable in fr/fr, fr/Δ and frCR/frCR 
mutant skin (Fig. 3). 
Aiming to investigate CAP1/Prss8 expression at the transcriptional level, we performed 
quantitative real time PCR analyses on skin, lung, kidney and colon extracts of fr/fr, fr/Δ 
mutant mice and control littermates. For all analyzed organs, mice carrying Δ/+ alleles, 
presented a significant (50%) reduction in the expression of CAP1/Prss8 when compared to 
wild-type animals, as it might be predicted from the absence of one CAP1/Prss8 allele. 
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Decreased CAP1/Prss8 expression was detected also in fr/Δ heterozygous, but it was 
significant only in the kidney. CAP1/Prss8 mRNA levels in fr/fr mutants did not differ from 
that of wild-type animals (Fig. 4A). Analogous analyses in the skin of frCR/frCR mutant rats in 
comparison to wild-types revealed a significant two-fold increase in the mRNA expression of 
CAP1/Prss8. In contrast, CAP1/Prss8 was significantly reduced in the distal colon (Fig. 4B), 
while no significant changes were observed among the different genotypes in lung and 
kidney.  
Finally, we performed western blot analyses using CAP1/Prss8 antibody on kidney, lung and 
alveolar epithelial cell extracts from fr mice and frCR rats, respectively. CAP1/Prss8 detection 
in fr/Δ and fr/fr mice evidenced a preferential core-glycosylated state of the mutant protein in 
comparison with the wild-type (Fig 4C). CAP1/Prss8 detection in frCR/frCR rats evidenced a 
preferential fully-glycosylated state compared to controls (Fig 4D). These data are entirely in 
accordance with the results obtained in vitro. 
 
Reduced body weight and dehydration defects in frCR/frCR rats.  
fr/fr and fr/Δ mouse mutants did not present differences in body weight in comparison with 
controls (Fig. 5A). frCR/frCR rats appeared smaller and exhibited a significantly lower body 
weight compared to wild-type and heterozygous littermates (Fig. 5B). To investigate whether 
the macroscopical and histological defects in fr/fr, fr/Δ and frCR/frCR mutants were 
accompanied by functional abnormalities of the skin, and to explore the ability of this organ 
to protect the body against excessive dehydration, we measured the trans epidermal water loss 
(TEWL). fr/fr and fr/Δ mouse mutants did not differ from controls with respect to the TEWL 
(Fig. 5C). In contrast, frCR/frCR rats exhibited a significant increase in the TEWL, suggesting 
that the skin barrier is compromised in these animals (Fig. 5D). Moreover, frCR/frCR rats 
presented diarrhea accompanied by increased stool hydration (Fig. 5E and F).  
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Significantly decreased ENaC activity in the distal colon of fr/fr, fr/Δ and frCR/frCR 
animals  
CAP1/Prss8 can increase ENaC-mediated sodium currents 6,31. To query the effect of 
CAP1/Prss8 V170D and G54-P57 deletion mutations on ENaC activity in vivo, the amiloride-
sensitive rectal potential difference was measured in the distal colon of both, fr mouse and 
frCR rat animal models. Since amiloride is a specific and potent inhibitor of ENaC 33, the 
amiloride-sensitive potential difference is an indirect indicator of ENaC function. Rectal 
potential difference in rodents follows circadian variation, reflecting differential metabolic 
activity of the animals during the day 34. We therefore performed in vivo measurements both 
in the morning and in the afternoon of two different days. Δ/+ and fr/+ heterozygotes did not 
manifest differences compared to the wild-types. fr/fr and fr/Δ mice revealed a significant 
decrease in the amiloride-sensitive potential difference, reflecting a significantly reduced 
ENaC activity in the distal colon (Fig. 6A). As fr/fr and fr/Δ mice, frCR/frCR rats demonstrated 
a significant less negative potential difference. Surprisingly, frCR/+ heterozygous rats showed 
reduced potential difference only in the morning, while in the afternoon the values were not 
different from wild-types (Fig. 6B). 
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DISCUSSION 
In this manuscript we study whether the spontaneous V170D and G54-P57 deletion mutations 
within the CAP1/Prss8 gene of ‘frizzy’ mice (fr) and ‘hairless’ rats (frCR) respectively, may 
cause their skin phenotypes and have additional consequences on the homeostasis of various 
organs where CAP1/Prss8 is expressed. 
In silico experiments indicated that the mutation V170D may alter CAP1/Prss8 protein 
structure because of unfavorable interactions of hydrophobic side-chains with polar Asp, and, 
most likely, the change of V170 to Asp would lead a more severe modification of the three-
dimensional configuration than the 2.4 Kcal loss of energy upon mutation to Ala. G54-P57 
residues in CAP1/Prss8 resulted solvent exposed, and their deletion could have a considerable 
impact on folding and architecture of the protein. These alterations of the protein structure 
may modify the interaction of CAP1/Prss8 with its effectors. We and other researchers have 
demonstrated that CAP1/Prss8 can increase the activity of the epithelial sodium channel 
ENaC in various expression systems 8,31,35, therefore CAP1/Prss8 activity can be evaluated by 
measuring ENaC currents. When we injected CAP1/Prss8 V170D and G54-P57 deletion 
mutants in the Xenopus oocytes, we observed that these mutations do not prevent the 
expression of the protein at the plasma membrane and their capability to activate the channel 
when co-expressed. However, the ability of CAP1/Prss8 V170D and G54-P57 deletion 
mutants to stimulate ENaC appeared significantly decreased. Western blot analyses and pulse-
chase experiments revealed a differential glycosylation state of the two mutant proteins in 
comparison with the wild-type CAP1/Prss8, evidencing a preferential core-glycosylated state 
of the V170D mutant versus a preferential fully-glycosylated state of the G54-P57 deletion 
mutant, indicating an increased retention of the V170D mutant in the endoplasmic reticulum 
(ER) and enhanced intracellular transport of the G54-P57 deletion mutant. In addition to the 
changes in the glycosylation state, pulse-chase experiments demonstrated that the degradation 
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and thus the stability of the mutant proteins do not change in comparison with the wild-type. 
However, what it does differ is the amount of energy lost upon mutation of V170 and W56 to 
Ala, as indicated by in silico alanine scanning. This loss of energy might modify the three-
dimensional conformation of the mutant proteins, that may be responsible of a differential 
glycosylation state, and eventually reduce their activity. 
To determine the role of CAP1/Prss8 in the different tissues, we previously deleted the mouse 
CAP1/Prss8 gene locus, located on chromosome 7, in a temporally and/or tissue-specific 
manner 19, and revealed crucial roles for this serine protease at least in the skin and in the lung 
7,6,1. fr/fr, fr/Δ mice and frCR/frCR rats displayed a significant reduction in the embryonic 
viability compared to the expected Mendelian inheritance, coinciding with the prenatal 
lethality of the CAP1/Prss8 knock-out mice, and strongly indicating a pleiotropic role of 
CAP1/Prss8 in embryonic development. Very interestingly, similar histopathological 
alterations occurred in the skin of fr/fr, fr/Δ and frCR/frCR animals, denoting that both mouse 
and rat skin structure is sensitive to CAP1/Prss8 mutations and altered function. Skin 
anomalies in ‘frizzy’ and ‘hairless’ animals did not appear to be accompanied by 
inflammation, thus these defects might originate during embryonic development and hair 
morphogenesis. Interestingly, frCR/frCR rats exhibited, in addition to alopecia and 
hyperkeratosis, an increase in the size and number of sebaceous glands. Sebum is a mixture of 
lipids 36 that coat the fur as a hydrophobic protection against dehydration and for heat 
insulation 37, and frCR/frCR animals may compensate their excess in loss of water through the 
skin by increasing the production of sebum.  
The fr mutation first appeared in 1949 at the Jackson Laboratory, and was identified in 1951 
by Falconer and Snell on a mixed genetic background that included the genetically linked 
recessive visible markers pink-eyed dilution (p), chinchilla (Tyrch), and shaker-1 (Myo7a) 38. 
We consider unlikely that those or other additional mutations in fr/fr animals could contribute 
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to the phenotype, since the same phenotype is maintained or even enhanced in the fr/Δ 
animals, and absent in the heterozygotes. In contrast, we can not exclude the implications of 
additional recessive mutations on the phenotype of frCR/frCR rats, and a complementation test 
could solve this issue, but so far CAP1/Prss8 knock-out alleles in rats are not available. 
Additional mutations in frCR/frCR animals could be responsible of the baldness and of the 
permeability defects observed in the skin and in the intestine of mutant rats, but not in fr/fr 
and fr/Δ mice. Alternatively, baldness and permeability defects in frCR/frCR rats could be the 
result of more severe consequences generated by the CAP1/Prss8 G54-P57 deletion mutation 
compared to the CAP1/Prss8 V170D mutation, or might be species-dependent.  
Although decreased in the distal colon, CAP1/Prss8 transcription levels increased in the skin 
of frCR/frCR rats, and a tendency for CAP1/Prss8 mRNA levels to augment could be noticed 
also in fr/Δ mice, not only in the skin but also in colon and lung. These data show a different 
transcriptional regulation of mutated CAP1/Prss8 in different organs, and a transcriptional up-
regulation of mutated CAP1/Prss8 in fr/Δ mice, that might be due to compensatory effects.  
Dehydration defects, either caused by skin or intestine anomalies, are often accompanied by 
body weight loss 39,40. Both skin-specific CAP1/Prss8 knock-out and CAP1/Prss8 
overexpressing mice presented increased skin dehydration accompanied by loss in body 
weight 7,1 and the tight junction functionality was defective in the skin-specific CAP1/Prss8 
knock-outs 7. Similarly, frCR/frCR rats showed significant reduction in body weight and 
manifested increased loss of water through the skin and intestine, evidencing epidermal 
permeability barrier defects that might be due to an effect of mutant CAP1/Prss8 on tight 
junctions and/or on sodium and therefore water reabsorption. ENaC activity resulted 
dramatically reduced in the distal colon of mutant mice and rats, and this decrease resulted of 
the same extent as that observed in intestine-specific CAP1/Prss8 knock-out mice (Sumedha 
Malsure et al., manuscript in preparation, Edith Hummler laboratory). These data indicate that 
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fr/fr, fr/Δ animals exhibit  the same reduction in the basal activity of ENaC as that of 
CAP1/Prss8 loss-of-function mutants.  
The three subunits of ENaC are expressed by surface epithelial cells of the distal colon 41 and 
several serine proteases that activate ENaC in vitro are also expressed in the gastrointestinal 
tract, with a tissue distribution broader than ENaC. CAP1/Prss8 is present in stomach and 
colon in rats, and in stomach, small intestine and distal colon in mice 35,31. The activity of 
ENaC depends on more than one serine protease, and we have previously shown that the 
serine protease CAP3/matriptase is able to increase 6 to 10-fold ENaC currents 31. It is 
noteworthy that both skin-specific deletion of CAP1/Prss8 and complete abrogation of 
CAP3/matriptase in mice caused leaky skin barrier 42,7, and that intestine-specific deletion of 
CAP3/matriptase provoked colon enlargement, persistent diarrhoea and increased intestinal 
paracellular permeability 43. Moreover, CAP1/Prss8 and CAP3/matriptase are constitutively 
co-localized in most epithelia 44 and have been proposed to be involved in the same 
proteolytic cascade 11,45. Thus, it is presumable that CAP1/Prss8 and CAP3/Tmprss14 
cooperate to maintain the homeostasis of different organs.  
In conclusion, the present study shows that both fr mouse and frCR rat models share similar 
features, like reduced embryonic viability, abnormal allocation of hair follicles in the dermis, 
and reduced amiloride-sensitive sodium current in the distal colon. All together these data 
support that fr and frCR are mutant alleles of the CAP1/Prss8 gene. fr and frCR therefore appear 
as suitable models for CAP1/Prss8 decreased function in the whole organism, and the 
consequences of mutated CAP1/Prss8 on its effectors and related pathways will be the object 
of further research. 
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Figure legends  
 
Figure 1. A: Homology model of the mouse CAP1/Prss8 tertiary protein structure constructed 
on the crystal structure-based homology model of the human CAP1/Prss8. Val170 residue, 
mutated into Asp in the fr mouse variant (upper panels, entire and zoomed view) and the 
Gly54-Gln-Trp-Pro57 fragment, deleted in the frCR rat variant (lower panels, entire and 
zoomed view) are highlighted in red. The residues of the serine protease active site, Asp134, 
His85 and Ser238 are represented in yellow. The hydrophobic environment of Val170 
consists of Ile45, Leu191 and Val256 shown in dark blue, as well as Asp237 in cyan. Gly54-
Pro57 interact with adjacent residues: Trp triad formed by Trp 56 (red) and Trp58 and Trp250 
(in dark green), Gln190 (in cyan) side chain forming hydrogen bond with Trp56 and hydrogen 
bond formed by Gln55 and Lys52 backbone. B: Amino acid alignment of the full length 
protein of mouse (gi: 19111160), rat (gi: 20301968) and human (gi: 4506153) CAP1/Prss8 
performed using the ClustalW2 multiple sequence alignment program 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/ Date of accession to the website: 17 August 
2011). Mouse and rat share 92% of CAP1/Prss8 sequence identity, mouse and human 77%, 
and rat and human 75%. The amino acids of the catalytic triad (His, Asp, Ser) are indicated by 
arrows. The four residues deleted in the frCR rat (Gly, Gln, Trp, Pro) and the Val170 
substituted with Asp in the fr mouse variants are indicated in red, and result conserved among 
these species. Stars indicate identical amino acid residues, double dots and dots indicate 
amino acids with similar and less similar side chain proprieties, respectively.  
 
Figure 2. A: CAP1/Prss8 immunofluorescence (green) performed in Xenopus oocytes 
injected with ENaC and CAP1/Prss8 wild-type, V170D and G54-P57 deletion mutant cRNA. 
BF: bright field. B: Oocytes were injected as indicated and Western blot analyses were 
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performed on cell lysates using CAP1/Prss8 and beta-actin antibodies. Two representative 
experiments (exp. 1 and exp. 2) are shown and quantification relative to beta-actin was 
performed on a total of four independent experiments each consisting of at least five oocytes 
injected per condition. C: Oocytes were injected as in B and protein extracts were treated (+) 
or not (-) with PNGase F in order to de-glycosylate the proteins and then subjected to Western 
blot analysis using CAP1/Prss8 antibody. f: fully-glycosylated, c:core-glycosylated, n: non- 
glycosylated. D: HEK-293 cells were transfected as indicated and protein extracts were 
treated (+) or not (-) with PNGase F in order to de-glycosylate the proteins and then subjected 
to Western blot analysis using CAP1/Prss8 antibody. f: fully-glycosylated, c:core-
glycosylated, n: non- glycosylated. This figure is representative of three independent 
experiments. E: Oocytes were injected as indicated and subjected to 6-h pulse (P), 4- (C1) and 
16-h (C2) chase periods. After the pulse-chase periods, protein extracts were prepared and 
subjected to non-denaturing immune-precipitations using CAP1/Prss8 antibody. Two 
experiments (exp. 1 and exp. 2) are shown and are representative of three independent 
experiments each consisting of fifteen oocytes injected per condition. f: fully-glycosylated, 
c:core-glycosilated. F: Amiloride-sensitive sodium currents from four independent 
experiments pulled together each consisting of at least five oocytes measured per condition 
prior to and after trypsin perfusion. The currents measured before the perfusion of the oocytes 
with trypsin were normalized to currents measured after trypsin perfusion. ***p<0.001 
 
Figure 3. Hematoxylin and eosin staining of skin, colon, lung and intestine in fr mouse (+/+, 
fr/+, ∆/+, fr/∆, fr/fr) and frCR rat (+/+, frCR/+, frCR/frCR) variants, performed in young-adult 
animals. Scale bar indicates 20 µm.   
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Figure 4. A: CAP1/Prss8 mRNA levels, relative to beta-actin, investigated by quantitative 
real time PCR, in lung, skin, colon and kidney of fr mice (+/+ n=10; fr/+ n=6; ∆/+ n=8; fr/∆ 
n=4; fr/fr n=9 number of analyzed animals). B: CAP1/Prss8 mRNA levels, relative to beta-
actin, investigated by quantitative real time PCR, in lung, skin, colon and kidney of frCR rats 
(+/+ n=4; frCR/+ n=4; frCR/frCR n=4 number of analyzed animals). *p<0.05, **p<0.01, 
***p<0.001. C: Western blot analysis performed on kidney extracts from fr mice using 
CAP1/Prss8 antibody. f: fully-glycosylated, c:core-glycosylated, a: aspecific band. Analogous 
results were obtained from lung extracts. Three animals per genotype were analyzed. D:  
Western blot analysis using CAP1/Prss8 antibody performed on lung alveolar epithelial cells 
isolated from frCR rats. f: fully-glycosylated, c:core-glycosylated. Two animals per genotype 
were analyzed. 
 
Figure 5. A: Body weight measurements expressed in grams (gr.) of fr mice (+/+ n=12; fr/+ 
n=15; ∆/+ n=23; fr/∆ n=13; fr/fr n=22 number of analyzed animals), performed in young-
adult animals. n.s.= non significant. B: Body weight measurements expressed in grams (gr.) 
of frCR rats (+/+ n=8; frCR/+ n=8; frCR/frCR n=10; ***p<0.001, male rats only), performed in 
young-adult animals. Same results were obtained for female rats (+/+ 283±6.2 n=6; frCR/+ 
296±6.6 n=7; frCR/frCR 259±12.1 n=4; p<0.05). C: Trans-epidermal water loss (TEWL) 
measurements of fr mice (+/+ n=10; fr/+ n=5; ∆/+ n=8; fr/∆ n=5; fr/fr n=9) expressed in 
grams on square meters per hour (gr./[m2h]). D: TEWL measurements of frCR rats (+/+ n=4; 
frCR/+ n=4; frCR/frCR n=4; *p<0.05) expressed in grams on square meters per hour (gr./[m2h]). 
E: Representative pictures of the intestinal content of frCR/frCR and wild-type rats clearly show 
an increased liquid content in the stools of the frCR/frCR mutants. F: Faeces water content, 
assessed as difference between freshly collected and completely dehydrated stools (+/+ n=6; 
frCR/+ n=3; frCR/frCR n=7; *p<0.05). 
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Figure 6. A: Amiloride-sensitive rectal potential difference (PD), reflecting ENaC activity 
and expressed in mV, measured in the distal colon of fr mice (+/+, n=12; fr/+ n=12; ∆/+ 
n=13; fr/∆ n=10; fr/fr n=10). +/+ versus fr/fr, p<0.05. +/+ versus fr/∆, p<0.01. B: Amiloride-
sensitive rectal potential difference (PD), reflecting ENaC activity and expressed in mV, 
measured in the distal colon of frCR rats (+/+ n=4; frCR/+ n=4; frCR/frCR n=4). Measurements 
were performed both in the morning (A.M.) and in the afternoon (P.M.) of two different days 
(day 1 and day 2). +/+ versus frCR/frCR, p<0.05. 
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Table I 
Inheritance of the fr, Δ and frCR mutations. Number of animals per genotype is indicated. 
 
fr genotype +/+ fr/+ ∆/+ fr/∆ fr/fr 
Breeding pairs      
fr/+ x ∆/+, n=111 42 32 30 7 - 
Observed % 38 29 27 6 - 
Expected % 25 25 25 25 - 
χ2 test 21.3 p<0.001     
      
fr/∆ x fr/+, n=95  40 28 12 15 
Observed % - 42 29 13 16 
Expected % - 25 25 25 25 
χ2 test 22.0 p<0.01     
      
frCR genotype +/+ frCR/+ frCR/frCR   
Breeding pairs      
frCR/+ x frCR/+, n=60 12 42 6   
Observed % 20 70 10   
Expected % 25 50 25   
χ2 test 18.0 p<0.01     
      
frCR/+ x frCR/frCR, n=50 - 32 18   
Observed % - 64 36   
Expected % - 50 50   
χ2 test 7.8 p<0.01     
 
A B
V170
G54-P57
mouse  MALRVGLGLGQLEAVTILLLLGLLQSGIRADGTEASCGAVIQPRITGGGSAKPGQWPWQV 60    
rat    MALRVGLGLGQLEALFILLLIGLLQSRIGADGTEASCGAVIQPRITGGGSAKPGQWPWQV 60
human  MAQKGVLGPGQLGAVAILLYLGLLRSGTGAEGAEAPCGVAPQARITGGSSAVAGQWPWQV 60
       ** :  ** *** *: *** :***:*   *:*:**.**.. *.*****.** .*******
mouse  SITYDGNHVCGGSLVSNKWVVSAAHCFPREHSREAYEVKLGAHQLDSYSNDTVVHTVAQI 120
rat    SITYNGVHVCGGSLVSNQWVVSAAHCFPREHSKEEYEVKLGAHQLDSFSNDIVVHTVAQI 120
human  SITYEGVHVCGGSLVSEQWVLSAAHCFPSEHHKEAYEVKLGAHQLDSYSEDAKVSTLKDI 120
       ****:* *********::**:******* ** :* ************:*:*  * *: :*
mouse  ITHSSYREEGSQGDIALIRLSSPVTFSRYIRPICLPAANASFPNGLHCTVTGWGHVAPSV 180
rat    ISHSSYREEGSQGDIALIRLSSPVTFSRYIRPICLPAANASFPNGLHCTVTGWGHVAPSV 180
human  IPHPSYLQEGSQGDIALLQLSRPITFSRYIRPICLPAANASFPNGLHCTVTGWGHVAPSV 180
       *.*.** :*********::** *:************************************
mouse  SLQTPRPLQQLEVPLISRETCSCLYNINAVPEEPHTIQQDMLCAGYVKGGKDACQGDSGG 240
rat    SLQTPRPLQQLEVPLISRETCSCLYNINAVPEEPHTIQQDMLCAGYVKGGKDACQGDSGG 240
human  SLLTPKPLQQLEVPLISRETCNCLYNIDAKPEEPHFVQEDMVCAGYVEGGKDACQGDSGG 240
       ** **:***************.*****:* ***** :*:**:*****:************
mouse  PLSCPMEGIWYLAGIVSWGDACGAPNRPGVYTLTSTYASWIHHHVAELQPRVVPQTQESQ 300
rat    PLSCPIDGLWYLAGIVSWGDACGAPNRPGVYTLTSTYASWIHHHVAELQPRAVPQTQESQ 300
human  PLSCPVEGLWYLTGIVSWGDACGARNRPGVYTLASSYASWIQSKVTELQPRVVPQTQESQ 300
       *****::*:***:*********** ********:*:*****: :*:*****.********
mouse  PDGHLCNHHPVFSSAAAPKLLRPVLFLPLGLTLGLLSLA---- 339
rat    PDGHLCNHHPVFNLAAAQKLSRPILFLPLSLTLGLFSLWLEH- 342
human  PDSNLCGSHLAFSSAPAQGLLRPILFLPLGLALGLLSPWLSEH 343
       **.:**. * .*. *.*  * **:*****.*:***:*      
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